📞 +91 9822924050
✉️ sales@klexagen.com
KlexaGen Private Limited is a leading Contract Research and Manufacturing Services (CRAMS) based in India that offers innovative and comprehensive services to the pharmaceutical industry. Founded in 2022, KlexaGen has quickly established itself as a reliable partner providing a complete range of research and development services for pharmaceutical Industries.
KlexaGen's team of experienced professionals is committed to providing high-quality solutions to meet the unique needs of their clients, with state-of-the-art facilities and cutting-edge technology, KlexaGen is well-equipped to deliver customized solutions through cost-effective and time-efficient methods. The organization has an unwavering commitment to excellence, and quality assurance, making it a trusted partner for pharmaceutical companies looking to innovate and develop new drugs.
KlexaGen Pvt. Ltd., we share the vision of being a global leader in life-sciences services. We intend to achieve this by working together towards the common goal of delivering the best-in-class value-added scientific services across the R&D spectrum.
To consistently deliver value-added scientific solutions with speed and quality, while ensuring safety and compliance.
We regard it as a privilege to serve our customers. We make 100% customer satisfaction our overriding priority. We constantly try to create new opportunities for growth in our business. We maintain a professional work environment dedicated to excellence and quality, setting the highest standards for ourselves.
Contract research and custom synthesis
Synthesis of API impurities, reference standards & metabolites
Unknown impurity isolation, characterization, and identification
Route scouting and process development
Photo-redox chemistry – Modern Chemistry Tool
Balasaheb has over fifteen years of expertise in synthetic medicinal chemistry, scale-up, and process development. He has led initiatives in the fields of oncology, inflammation, etc. while employed as a scientist in Lupin’s discovery chemistry department. He was employed at the Contract Research Organization (CRO) Chembiotech, where he obtained practical experience working on joint projects with outside partners. Balasaheb’s vast experience in the fields of small heterocyclic compounds, library synthesis, steroids, and carbohydrates suggests that he has a solid foundation in medicinal chemistry.
Dr. Summon Koul holds a Master's degree in Organic Chemistry from the University of Kashmir (1998) and a PhD from the University of Jammu (2003). During her doctoral research, she focused on isolating, characterizing, and semisynthetic conversions of biologically active natural products. After completing her PhD, she worked as a Research Associate at the Indian Institute of Science in Bengaluru, followed by a Postdoctoral Fellowship at Simon Fraser University in British Columbia, Canada, where she worked on the total synthesis of Triquinacenes.
For 13 years, Summon worked as a drug discovery Scientist and program leader at Advinus Therapeutics - a TATA Enterprise. In this role, she led in-house and collaborative drug discovery research projects with reputed multinational pharma companies such as Merck, Johnson and Johnson, USA, and Takeda, Japan. She has handled multi-crore projects and has been recognized for Best Awards in the Company. Her focus areas were Cardiovascular Diseases, Metabolic Disorders, and Inflammation. During this time, she also led CRO discovery projects in Eurofins Advinus (Advinus Therapeutics was acquired by Eurofins in 2017) in collaboration with companies like Medicines for Malaria Venture, Switzerland; Astellas, Japan; Nostrum Biodiscovery, Spain, and Foundation for Neglected Disease Research, India. She has over 16 publications in international journals of repute, book chapters, and eight patents to her credit.
